**Loneliness and Depression in Patients with Cancer During COVID-19**

Stephen Gallagher,1,2 Kate M Bennett3 & Louise Roper3

1 Department of Psychology, Centre for Social Issues Research, Study of Anxiety, Stress and Health Laboratory, University of Limerick, Limerick, Ireland

2 Health Research Institute, University of Limerick, Castletroy, Limerick, Ireland

3 Department of Psychology, University of Liverpool, Liverpool, UK

**Corresponding Author:**

Stephen Gallagher

Department of Psychology

University of Limerick

Castletroy

Co. Limerick

Republic of Ireland

[stephen.gallagher@ul.ie](mailto:stephen.gallagher@ul.ie)

+35361234899

<https://orcid.org/0000-0002-5471-7774>

Twitter @DrSGallagher

Word count: 2000 Inc abstract tables/references

Tables 2

Figure 1

**Abstract**

**Purpose:** Feelings of loneliness are likely to exacerbate risk of depression in people living with cancer during COVID-19. **Design and Methods**: Five hundred and eighteen people with cancer with data extracted from two waves (2017-19 and April 2020) of the Understanding Society UK dataset participated. **Findings:** An increased risk of depression was observed for cancer of the breast, prostate, blood, but not other cancers (e.g., lung, melanoma). After controlling for prior depression and other factors, it was loneliness during COVID-19, and not previous loneliness, that was predictive. Those currently lonely had a 4.5-fold increased risk of depression. These findings demonstrate that people living with cancer are at increased risk of developing depression during COVID-19, and that feelings of isolation help explain this risk. **Implications:** These particular findings have implications for health promotion and intervention work and how best to support people who may feel lonely in this vulnerable group.

**Keywords:** COVID-19; Cancer; Depression; Isolation; Loneliness;

**Introduction**

Depression is common in patients with cancer and estimates range between 13% and 20% (Pitman et al., 2018) which are much higher than the 4.4% found for major depression in the general population (WHO., 2017). While prevalence rates can vary with age and gender of the patient, diagnosis, treatment and stage of cancer (Pitman et al., 2018), there are other biopsychosocial and behavioural causes such as feeling isolated from others and excessive alcohol and low physical activity (Sahin & Tan, 2012). Isolation, and loneliness in particular, is linked to poor coping skills, lower immunity, greater risk of mortality, and its effects on health is comparable to that of smoking (Cacioppo et al., 2015; Deckx et al., 2014; O'Suilleabhain et al., 2019). In patients with cancer, loneliness is associated with negative thoughts of their social situations and lack of social support (Deckx et al., 2014). Moreover, with COVID-19 restrictions of movement in place alongside changes to delivery or curtailment of medical services this is likely to exacerbated with implications for increased risk of depression (Holmes et al., 2020; Mohile et al., 2020). This is the focus of the present study. Thus, based on the above, it is hypothesised that 1) rates of depression in people living with cancer would be higher during COVID-19, and 2) the unintended consequences of COVID-19 restrictions, i.e., treatment cancelled, changes to health behaviours and feelings of loneliness would be predictive of depression risk in those living with cancer.

**Methods**

**Study design and participants**

A longitudinal design was employed with data extracted from Wave 9 (2017-19) (University of Essex et al., 2019) and the COVID-19 wave (April 2020)(University of Essex & Research., 2020 ) of the *Understanding Society* UK population study. Ethics were obtained by the University of Essex, UK (REC A (08/H0604/124). As the main study was conducted at the national level weights are provided for sub-group analysis. For our study analysis, participants had to respond ‘yes’ from a list of long-term conditions, in COVID-19 survey, to having cancer/malignancy and if yes, a follow-up question ascertained cancer types (e.g. breast, lung, prostate, skin/melanoma, bowel, bloods/leukemia, liver or other). Further, participants also had to have participated in Wave 9, and answer the same questions. From a sample of N=11,836, 518 people (4.4%) were eligible for analysis. Relationship, ethnicity, and job status were dichotomized (e.g., married/partnered vs single/divorced/widowed; White vs Black and minority ethnic (BME); employed vs unemployed/retired). As an indicator or objective social isolation, i.e. living alone, living arrangements were ascertained by asking if they lived with partner (yes/no), and if there were other people they shared the home with across different age brackets: ages 0-4, 5-15, 16-18, 19-67, and 70 +. A simple numerical figure was given and these were totalled, and then recoded into, 0= living alone, and 1 = living with others (see Table 1 for group characteristics).

**Depression**

Depression was captured by the 12-item General Health Questionnaire (GHQ)(Goldberg et al., 1997). Items (e.g., unhappy or depressed) are scored as 1= not at all; 2= no more than usual; 3= rather more than usual; 4= much more than usual. As we were interested in probable depression rather than symptomology, responses of 1 or 2 are scored as 0, and responses of 3 or 4 are scored as 1. A total score ≥6 is specific and sensitive at identifying those with or without a depressive disorder (Lundin et al., 2016). In the present internal consistency was high, with α = .91 for pre-COVID-19 and during COVID-19 α = .90.

**Access to treatment during COVID-19**

Access to treatment was assessed by asking: “Has your treatment plan(s) been changed in any way?, 1= Yes, consultations/treatments cancelled or postponed by NHS, 2= Yes, alternative treatment provided, 3= Yes, I cancelled or postponed treatment, and 4= No, treatment continuing as planned.

**Loneliness**

Loneliness at both time-points wasassessed by a single item: “In the last 4 weeks, how often do you feel lonely?” with three responses, 1= Hardly ever or never; 2= Sometimes; 3= Often.

**Health Behaviours**

Alcohol intake was assessed with “Thinking about the last 4 weeks, how often did you have a drink containing alcohol? 1= Never, 2= Once, 3= 2-4 times in total, 4= 2-3 times per week, 5= 4-6 times per week, and 6= Daily. Those reported once and 2-3 times were recoded as 2, and, 6-6 times a week and daily as 3. Thus, giving us three categories, 1= never, 2 = 1- a week, and 3 = almost daily. Walking was ascertained from this “During the last 7 days, on how many days did you walk for at least 10 minutes at a time?” and had an open response [Numeric] days per week.

**Statistical Analysis**

The sample was weighted to provide a representative national sample, taking into account survey design and non-response. IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA)(IBM, 2014) was used for analysis. No outliers were observed and data were normally distributed. Tests of differences were used to examine group differences on sociodemographic, health and outcome variables. Variations in degrees of freedom reflect missing data (e.g. walking). A step-wise hierarchical logistic regression examined the predictors of depression across those living with cancer. In this analysis, confounding variables (i.e., sociodemographics, pre-existing depression and cancer groups) were entered in step 1, step 2 and Step 3 respectively with loneliness experienced during COVID-19 entered in step 4 of the model. Odds ratio (OR) is the effect size.

**Results**

In line with common cancer types in the UK, 26.3% had breast cancer, 14.9% had prostate, and 22.7% had blood cancers (22.7%). As there were lower numbers of bowel, liver, lung, skin and other types these were pooled into the ‘other’ category (36.1%) for analysis. As evidenced in Table 1, those with blood cancers were the youngest, while those with prostate were older men, and also more likely to be married. For breast cancer, 97% were women. There were no differences on any other sociodemographic, health behaviors or access to NHS treatment. However, those with blood cancers were more likely to be lonely ‘more often’ than other groups. Further, rates of depression increased over time for those with cancers of the breast, prostate and bloods but not ‘other’. Those with cancers of the blood were the most affected, i.e. an additional 10% now categorized as depressed.

[Insert Table 1 About Here]

In stepwise logistic regression, controlling for confounding factors (See Table 1 for group differences) in Step 1, and prior depression at Step 2, and cancer group at Step 3, the between groups differences on current depression evident in Table 1 was abolished; OR = 1.18 (95% confidence interval (95% CI), 0.92-1.52)), *p* =.19. However, loneliness experienced during COVID-19 in Step 4 was a significant predictor of depression in cancer patients. Those who reported higher levels of loneliness during the current crisis had an almost 4.5 times greater risk of depression, OR = 4.54. As can be seen in Figure 1, over 40% of those who were depressed reported being lonely ‘sometimes’, whereas this was only evident in 19% of those not depressed. Also, over 20% of those with depression versus 2.1% of not depressed reported being ‘lonely’(χ2 (2) = 77.82, *p* <.001).

[Insert Table 2 & Figure 1 about here]

**Discussion**

Our findings demonstrate that people living with the most common cancers (breast, prostate and blood) appear to be at an increased risk of depression during COVID-19, and that feelings of isolation help explain this risk. While loneliness can be experienced by anyone, it is the enforced isolation, due COVID-19 restrictions that was the strongest predictor. Pre-COVID depression explained 12% while those experiencing loneliness during the pandemic were 4.5 times at a higher risk of current depression symptoms. This in in accord with recent research suggesting that loneliness, as an unintended consequence of COVID-19 restrictions, will be damaging for those with existing depression (Holmes et al., 2020). In fact, social and physical activities, particularly ones face to face with family and/or in groups were among the first areas of interaction that were prohibited under guidance from the UK government during this period, thus one can see how those affected by cancer would become more isolated. Further, this would also be compounded against the backdrop of the reduction of health and social care services- that may typically support people in need. This is likely to have had the most impact on people living with cancer who seek social support from these groups.

Though there are strengths to our paper, longitudinal design, population level data, there are also limitations. First, there was no data on stage of cancer, treatment type, or duration of illness, factors which are also known to be associated with risk of depression.

Our findings have important implications, as it is likely that some restrictions will be in place for some time until effective COVID-19 treatments are found. Therefore, the levels of loneliness may persist over time to become chronic which may worsen the risk of depression in cancer patients. Further, as health professionals we need to think about how to mitigate this risk. Interventions should focus on reducing loneliness and increasing social interaction within the scope of the ‘new world’ of reduced face to face support and increased online support. For example, building online communities of peer support where virtual interactions can take place, and where possible providing tele-health services for health and social care consultations.

**References**

Cacioppo, S., Grippo, A. J., London, S., Goossens, L., & Cacioppo, J. T. (2015). Loneliness: clinical import and interventions. *Perspect Psychol Sci, 10*(2), 238-249. <https://doi.org/10.1177/1745691615570616>

Deckx, L., van den Akker, M., & Buntinx, F. (2014). Risk factors for loneliness in patients with cancer: a systematic literature review and meta-analysis. *Eur J Oncol Nurs, 18*(5), 466-477. <https://doi.org/10.1016/j.ejon.2014.05.002>

Goldberg, D. P., Gater, R., Sartorius, N., Ustun, T. B., Piccinelli, M., Gureje, O., & Rutter, C. (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. *Psychol Med, 27*(1), 191-197. <https://doi.org/10.1017/s0033291796004242>

Holmes, E. A., O'Connor, R. C., Perry, V. H., Tracey, I., Wessely, S., Arseneault, L., Ballard, C., Christensen, H., Cohen Silver, R., Everall, I., Ford, T., John, A., Kabir, T., King, K., Madan, I., Michie, S., Przybylski, A. K., Shafran, R., Sweeney, A., Worthman, C. M., Yardley, L., Cowan, K., Cope, C., Hotopf, M., & Bullmore, E. (2020). Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry*. <https://doi.org/10.1016/S2215-0366(20)30168-1>

IBM. (2014). How to cite IBM SPSS Statistics or earlier versions of SPSS. <http://www-01.ibm.com/support/docview.wss?uid=swg21476197> (accessed September 24, 2020).

Lundin, A., Hallgren, M., Theobald, H., Hellgren, C., & Torgen, M. (2016). Validity of the 12-item version of the General Health Questionnaire in detecting depression in the general population. *Public Health, 136*, 66-74. <https://doi.org/10.1016/j.puhe.2016.03.005>

Mohile, N. A., Blakeley, J. O., Gatson, N. T. N., Hottinger, A. F., Lassman, A. B., Ney, D. E., Olar, A., Schiff, D., Shih, H. A., Strowd, R., van den Bent, M. J., & Ziu, M. (2020). Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic. *Neuro Oncol*. <https://doi.org/10.1093/neuonc/noaa090>

O'Suilleabhain, P. S., Gallagher, S., & Steptoe, A. (2019). Loneliness, Living Alone, and All-Cause Mortality: The Role of Emotional and Social Loneliness in the Elderly During 19 Years of Follow-Up. *Psychosom Med, 81*(6), 521-526. <https://doi.org/10.1097/PSY.0000000000000710>

Pitman, A., Suleman, S., Hyde, N., & Hodgkiss, A. (2018). Depression and anxiety in patients with cancer. *BMJ, 361*, k1415. <https://doi.org/10.1136/bmj.k1415>

Sahin, Z. A., & Tan, M. (2012). Loneliness, depression, and social support of patients with cancer and their caregivers. *Clin J Oncol Nurs, 16*(2), 145-149. <https://doi.org/10.1188/12.CJON.145-149>

University of Essex, Institute for Social and Economic Research, & NatCen Social Research, K. P. (2019). University of Essex, Institute for Social and Economic Research, NatCen Social Research, Kantar Public. (2019). Understanding Society: Waves 1-9, 2009-2018 and Harmonised BHPS: Waves 1-18, 1991-2009. [data collection]. 12th Edition. UK Data Service. SN: 6614, <http://doi.org/10.5255/UKDA-SN-6614-13>.

University of Essex, & Research., I. f. S. a. E. (2020 ). Understanding Society: COVID-19 Study, 2020. [data collection]. UK Data Service. SN: 8644, <http://doi.org/10.5255/UKDA-SN-8644-1>.

WHO. (2017). Depression and Other Common Mental Health Disorders: Global Health Estimates *World Health Organisation,* [*https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1*(accessed](https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1(accessed) 18/06/2020).

Table 1. Sociodemographics, health and outcome variables across cancer types

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **Breast (*N*=136)** | **Prostate (*N*=77)** | **Bloods (*N*=117)** | **Others (*N*=187)** | **Test of difference** |
| Age Mean (SD) | 63.7 (11.49) | 68.4(8.21) | 59.2 (14.54) | 64.6(11.87) | F (3,515) = 10.86, *p* < .001 |
| Married/Partnered % | 68.1 | 85.9 | 70.9 | 75.4 | χ2 (3) = 8.91, *p* =.03 |
| Sex (female) % | 97.1 | 0.0 | 53.0 | 46.5 | χ2 (3) = 196.36, *p* < .001 |
| Ethnicity % (White) | 98.5 | 93.5 | 94.1 | 97.3 | χ2 (3) = 5.79, *p* = .12 |
| Income (Monthly £) | 1,795.4 (4,477.12) | 1,168.7 (1,518.95) | 2,220.4 (5,744.44) | 1,893.5 (1,543.13) | F (3,515) = 0.39, *p* = .79 |
| Employed % (no) | 61.2 | 66.2 | 55.1 | 59.4 | χ2 (3) = 2.56, *p* =.46 |
| Living alone %(yes) | 19.9 | 12.8 | 16.1 | 18.7 | χ2 (1) = 2.05, *p* =.56 |
| Alcohol almost daily % (yes) | 37.2 | 45.8 | 43.1 | 46.8 | χ2 (3) = 2.12, *p* =.54 |
| Days Walking Mean ( SD) | 5.6(1.89) | 5.4(1.96) | 4.95(2.34) | 5.4(2.12) | F (3,431) = 1.81, *p* = .14 |
| PreCOVID-Lonely (often) | 5.2 | 3.9 | 5.2 | 9.7 | χ2 (6) =8.51, *p* =.20 |
| COVID-Lonely (often) | 5.2 | 1.3 | 9.4 | 6.5 | χ2 (6) = 13.76, *p* = .03 |
| NHS cancelled treatment %(yes) | 51.9 | 58.3 | 51.9 | 53.4 | χ2 (9) = 7.32, *p* =.60 |
| PreCOVID-Depression % (yes) | 14.7 | 5.2 | 18.1 | 13.9 | χ2 (3) = 6.71, , *p* =.08 |
| COVID-Depression % (yes) | 19.7 | 9.1 | 28.1 | 13.5 | χ2 (3) = 14.74, *p* = .002 |

Table 2. Hierarchical logistic regression predicting depression in cancer patients

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | **B** | **OR** | ***p*** | **95%CI Lower** | **95%CI Upper** |
| **Step 1** |  |  |  |  |  |
| Age | -.02 | 0.98 | **.001** | 0.97 | 0.98 |
| Partnered | .29 | 1.34 | **.001** | 1.20 | 1.50 |
| Gender | .67 | 1.96 | **.001** | 1.77 | 2.17 |
| **Step 2** |  |  |  |  |  |
| Age | -.01 | 0.98 | **.001** | 0.97 | .98 |
| Partnered | .15 | 1.16 | **.009** | 1.04 | 1.30 |
| Gender | .58 | 1.86 | **.001** | 1.67 | 2.07 |
| PreCOVID-Depression | .13 | 1.13 | **.001** | 1.12 | 1.14 |
| **Step 3** |  |  |  |  |  |
| Age | -.01 | .98 | .19 | 0.98 | 1.07 |
| Partnered | .50 | 1.65 | .07 | 0.95 | 2.86 |
| Gender | .43 | 1.53 | .15 | 0.85 | 2.75 |
| PreCOVID-Depression | .12 | 1.13 | **.001** | 1.09 | 1.18 |
| Cancer groups | .15 | 1.16 | .27 | 0.89 | 1.50 |
| **Step 4** |  |  |  |  |  |
| Age | -.01 | .99 | .56 | 0.99 | 1.01 |
| Partnered | -.07 | .94 | .83 | 0.50 | 1.75 |
| Gender | .29 | 1.33 | .36 | 0.72 | 2.48 |
| PreCOVID-Depression | .11 | 1.12 | **.001** | 1.07 | 1.17 |
| Cancer Group | .21 | 1.23 | .14 | 0.94 | 1.61 |
| COVID-19 loneliness | 1.51 | 4.54 | **.001** | 2.97 | 6.94 |